Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Elizabeth Glaze, Ph.D., DABT

Branch Chief
Developmental Therapeutics Program
Toxicology and Pharmacology Branch
240-276-5822
|
glazee@mail.nih.gov

Dr. Elizabeth Glaze earned her Ph.D. in Pharmacology from the University of Michigan in 1999. There she evaluated the mechanism by which 5′-bromo-2′-deoxyuridine (BrdU) sensitizes human glioma cells to DNA alkylating agents. As a postdoctoral fellow at the University of Pennsylvania, she evaluated the role of polycyclic aromatic hydrocarbon (PAH) o-quinone-induced reactive oxygen species in the formation of 8-oxo-deoxyguanosine DNA adducts, and its relevance in tumor initiation. After her fellowship, Dr. Glaze joined the NIH in 2001, where she managed and provided advice on over a hundred preclinical toxicology/safety studies for cancer treatment, cancer prevention, and the prevention and treatment of infectious diseases caused by various biothreat agents. As branch chief of the Toxicology and Pharmacology Branch, she oversees an impressive group of senior scientists who perform the work described above. She heads a laboratory that develops in vitro assays that interrogate mechanisms of chemotherapy-induced toxicities and identifies compounds with the potential to reverse, prevent, or mitigate the chemotherapy-induced toxicities.

Email